FDA expands use of remdesivir to patients with high risk of hospitalization
USA
22 January, 2022, 09:40 am
Last modified: 22 January, 2022, 09:42 am
An ampule of Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues. Photo :Reuters
The US health regulator on Friday expanded its approval for the use of Gilead Sciences' antiviral drug remdesivir to treat non-hospitalized patients 12 years and older for the treatment of mild-to-moderate Covid-19 disease with high risk of hospitalization.
Previously, the use of Veklury was limited to patients requiring hospitalization.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.